11月25日,CDE官网显示,药捷安康的替恩戈替尼片拟纳入优先审评,用于既往至少接受过一种系统性治疗和FGFR抑制剂治疗的晚期、转移性或不可手术切除的胆管癌成人患者的治疗。替恩戈替尼(Tinengotinib, TT-00420)是药捷安康自主研发的一款多靶点激酶抑制剂,可同时靶向FGFR/VEGFR、JAK和Aurora激酶三大关键致癌通路。替恩戈替尼结构独特,其采用全新化学骨架,不深入结合...
Source Link11月25日,CDE官网显示,药捷安康的替恩戈替尼片拟纳入优先审评,用于既往至少接受过一种系统性治疗和FGFR抑制剂治疗的晚期、转移性或不可手术切除的胆管癌成人患者的治疗。替恩戈替尼(Tinengotinib, TT-00420)是药捷安康自主研发的一款多靶点激酶抑制剂,可同时靶向FGFR/VEGFR、JAK和Aurora激酶三大关键致癌通路。替恩戈替尼结构独特,其采用全新化学骨架,不深入结合...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.